Developer docs
API playgroundTry for free, no card

Search company profiles

LENZ Therapeutics

Full company profile

uuid00004bj

Namestring
LENZ Therapeutics
Legal namestring
LENZ Therapeutics, Inc.
Websiteurl
lenz-tx.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is a US biopharmaceutical company headquartered in Solana Beach, California, that develops and commercializes prescription therapeutics for presbyopia, the age-related loss of near vision. The company re-emerged under CEO Eef Schimmelpennink in 2021 with a $47M Series A, raised an $83.5M Series B in 2023, completed a reverse merger with Graphite Bio in March 2024 to list on Nasdaq, and received FDA approval in July 2025 for VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based prescription eye drop indicated for presbyopia in adults.

The company's core technology is a pupil-selective miotic formulation: aceclidine contracts the iris sphincter muscle to create a pinhole effect, increasing depth of focus and improving near vision for up to 10 hours from a single daily dose. Phase 3 CLARITY trials in over 600 participants showed 93% of subjects achieving 20/40 or better near vision within 30 minutes, with over 30,000 treatment days of safety data. US commercialization began in October 2025 through retail pharmacy distribution supported by a 117-representative field sales force targeting optometrists and ophthalmologists, in-office dispensing in 25 states, physician sampling, and a 'Make it VIZZable' direct-to-consumer campaign featuring Sarah Jessica Parker.

LENZ operates a dual revenue model. In the US it sells VIZZ directly as a prescription pharmaceutical, generating $1.6M in Q4 2025 (launch quarter) and $1.9M in Q1 2026 on roughly 25,000 paid prescriptions. Internationally, the company monetizes through licensing and distribution partnerships: Everest Medicines (Greater China, up to $85M in milestones plus tiered royalties), Laboratoires Théa (Canada, over $70M in milestones plus tiered double-digit royalties), Arrotex (Australia/New Zealand), Lunatus (Middle East), and Lotus Pharmaceutical (South Korea), with regulatory submissions filed at the FDA, EMA, UK MHRA, and South Korea MFDS. End customers are individual presbyopia patients (approximately 128M in the US and 1.8B globally), with no meaningful single-customer concentration.

Short descriptiontext

LENZ Therapeutics (NASDAQ: LENZ) is a biopharmaceutical company that commercializes VIZZ, the first and only FDA-approved aceclidine-based prescription eye drop for presbyopia in adults, sold directly in the US and through international licensing partners covering Greater China, Canada, Australia/New Zealand, the Middle East, and South Korea.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
presbyopia treatment, ophthalmic pharmaceuticals, aceclidine eye drops, near vision restoration, prescription eye care
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1VIZZ Product Sales
TypeOthers
Description

Revenue generated from commercial sales of VIZZ (aceclidine ophthalmic solution) 1.44% in the United States through prescriptions filled at pharmacies. Early commercial traction showing 25,000 paid prescriptions in Q1 2026 with 19% sequential growth.

ir.lenz-tx.com
2International Licensing and Royalties
TypeLicensing Royalties
Description

LENZ receives upfront payments, regulatory and commercial milestone payments, plus tiered royalties on net sales from international partners including Everest Medicines (up to $85M in milestones plus mid single-digit to low double-digit royalties for Greater China), Laboratoires Théa (over $70M plus tiered double-digit royalties for Canada), Arrotex (Australia/New Zealand), and Lunatus (Middle East).

ir.lenz-tx.com
3Private Investment (PIPE)
TypeOthers
Description

$30 million private investment from Ridgeback Capital via a PIPE agreement to support regulatory and commercial activities.

ir.lenz-tx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Marketing or Sales, Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1VIZZ
Description

VIZZ (aceclidine ophthalmic solution) 1.44% - the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

lenz-tx.com
Core offering1 text field

LENZ Therapeutics commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. The once-daily drop contracts the iris sphincter muscle to create a pinhole effect, restoring clear near vision for up to 10 hours. The company sells the product in the United States through retail pharmacies and a 117-representative sales force targeting eye care professionals, while licensing VIZZ to regional partners across Greater China, Canada, Australia/New Zealand, the Middle East, and South Korea.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93% of participants achieved 20/40 or better near vision within 30 minutes
+3 more records
Product overview1 text field

LENZ Therapeutics commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for treating presbyopia. The company developed LNZ100 and LNZ101 through Phase 3 clinical trials, with LNZ100 receiving FDA approval in July 2025 and being marketed as VIZZ. VIZZ is a once-daily prescription eye drop that improves near vision for up to 10 hours through pupil contraction creating a pinhole effect. LENZ is expanding globally through licensing partnerships while maintaining US commercialization directly.

Product and service1 record
1VIZZ (aceclidine ophthalmic solution) 1.44%
CategoryOphthalmic Pharmaceuticals
Description

The first and only FDA-approved aceclidine-based prescription eye drop for treating presbyopia in adults. Once-daily eye drop that improves near vision for up to 10 hours by creating a pinhole effect through pupil contraction. Validated through three Phase 3 clinical trials involving over 600 participants.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-24
Description

Exclusive licensing and commercialization agreement for VIZZ (aceclidine ophthalmic solution) in Australia and New Zealand. Arrotex receives exclusive rights to register and commercialize the presbyopia treatment while LENZ receives upfront payment plus share of gross margin from product sales. This is LENZ's fifth ex-U.S. partnership.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-07
Description

Everest Medicines acquired rights to develop, manufacture, and commercialize VIZZ (LNZ100) for presbyopia treatment in Greater China (mainland China, Hong Kong SAR, Macao SAR, and Taiwan) through an Asset Purchase Agreement with Corxel Pharmaceuticals. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones plus tiered mid single-digit to low double-digit royalties on net sales. NDA submitted in September 2025 with approval anticipated Q1 2027.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-05
Description

Exclusive distribution agreement for VIZZ (aceclidine ophthalmic solution) for treating presbyopia in the Middle East region, covering UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. LENZ receives upfront, regulatory and commercial milestone payments plus significant share of revenue. This is LENZ's fourth international commercialization partnership.

4Lotus Pharmaceutical
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-01
Description

Lotus Pharmaceutical submitted a New Drug Application (NDA) for VIZZ (LNZ100) in South Korea for the treatment of presbyopia following positive Phase 3 trial data. This submission marked the second regulatory step in Asia for VIZZ.

globenewswire.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-07
Description

Exclusive license and commercialization agreement for LNZ100 in Canada. Théa received exclusive rights to register and commercialize the aceclidine-based eye drop candidate for treating presbyopia. LENZ eligible to receive over $70 million in upfront, regulatory, and commercial milestone payments plus tiered double-digit royalties on net sales. This was LENZ's third international commercialization agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-21
Description

LENZ Therapeutics completed a merger with Graphite Bio, with the combined company trading on NASDAQ under ticker 'LENZ' starting March 22, 2024.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Allergan markets Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop and VIZZ's primary direct competitor. Same patient population (presbyopes), same delivery mechanism (topical ophthalmic drops), same prescriber base (optometrists/ophthalmologists).

TypeDirect peer
Description

Orasis is developing CSF-1 (low-dose pilocarpine) for presbyopia, positioning as another miotic-based eye drop competitor. Same therapeutic category, same target patient, same ECP channel; represents the next credible competitive threat to VIZZ's first-mover position.

TypeDirect peer
Description

Visus is developing BRIMOCHOL and other presbyopia therapeutics based on miotic mechanisms. Clinical-stage direct competitor with overlapping indication, mechanism class, and prescriber targeting.

TypeDirect peer
Description

Ocuphire is developing ophthalmic therapeutics for presbyopia and other refractive indications, including Nyxol. Same eye-care specialty pharmaceutical model, target prescribers, and indication overlap as LENZ.

TypeEmerging player
Description

Eyenovia develops ophthalmic pharmaceutical products using its Optejet dispenser platform, including presbyopia candidates (MicroLine/pilocarpine). Different delivery technology but same therapeutic indication and prescriber channel.

TypeBroad incumbent
Description

Bausch + Lomb is a global ophthalmic company with a broad portfolio including prescription eye drops, surgical products, and consumer vision care. While not focused exclusively on presbyopia, it serves the same ECP channel and competes for eye-drop market share.

TypeBroad incumbent
Description

Alcon is the global leader in eye care, spanning surgical, vision care, and pharmaceuticals. It is a major channel partner and a broad incumbent with overlapping ECP relationships and ophthalmic pharmaceutical capabilities.

TypeBroad incumbent
Description

Théa is a European ophthalmic specialty pharmaceutical company and LENZ's Canadian commercialization partner for VIZZ. Comparable specialty-ophthalmic pharma focus with similar product lines and prescriber relationships.

TypeBroad incumbent
Description

Novartis operates a significant ophthalmology franchise (including Xiidra and Lucentis) through Sandoz and the broader pharma portfolio. Broad incumbent with overlapping eye-care prescriber relationships and ophthalmic Rx portfolio.

TypeEmerging player
Description

Eyedetec is developing pharmaceutical eye drops for presbyopia and myopia. Clinical-stage emerging competitor with same therapeutic category, though smaller and earlier-stage than LENZ.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LENZ Therapeutics

Ophthalmic Pharmaceuticalslenz-tx.com

LENZ Therapeutics (NASDAQ: LENZ) is a biopharmaceutical company that commercializes VIZZ, the first and only FDA-approved aceclidine-based prescription eye drop for presbyopia in adults, sold directly in the US and through international licensing partners covering Greater China, Canada, Australia/New Zealand, the Middle East, and South Korea.

What LENZ Therapeutics does

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is a US biopharmaceutical company headquartered in Solana Beach, California, that develops and commercializes prescription therapeutics for presbyopia, the age-related loss of near vision. The company re-emerged under CEO Eef Schimmelpennink in 2021 with a $47M Series A, raised an $83.5M Series B in 2023, completed a reverse merger with Graphite Bio in March 2024 to list on Nasdaq, and received FDA approval in July 2025 for VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based prescription eye drop indicated for presbyopia in adults.

The company's core technology is a pupil-selective miotic formulation: aceclidine contracts the iris sphincter muscle to create a pinhole effect, increasing depth of focus and improving near vision for up to 10 hours from a single daily dose. Phase 3 CLARITY trials in over 600 participants showed 93% of subjects achieving 20/40 or better near vision within 30 minutes, with over 30,000 treatment days of safety data. US commercialization began in October 2025 through retail pharmacy distribution supported by a 117-representative field sales force targeting optometrists and ophthalmologists, in-office dispensing in 25 states, physician sampling, and a 'Make it VIZZable' direct-to-consumer campaign featuring Sarah Jessica Parker.

LENZ operates a dual revenue model. In the US it sells VIZZ directly as a prescription pharmaceutical, generating $1.6M in Q4 2025 (launch quarter) and $1.9M in Q1 2026 on roughly 25,000 paid prescriptions. Internationally, the company monetizes through licensing and distribution partnerships: Everest Medicines (Greater China, up to $85M in milestones plus tiered royalties), Laboratoires Théa (Canada, over $70M in milestones plus tiered double-digit royalties), Arrotex (Australia/New Zealand), Lunatus (Middle East), and Lotus Pharmaceutical (South Korea), with regulatory submissions filed at the FDA, EMA, UK MHRA, and South Korea MFDS. End customers are individual presbyopia patients (approximately 128M in the US and 1.8B globally), with no meaningful single-customer concentration.

LENZ Therapeutics firmographics

Firmographics
Name
LENZ Therapeutics
Legal name
LENZ Therapeutics, Inc.
Website
https://lenz-tx.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
LENZ Therapeutics (NASDAQ: LENZ) is a biopharmaceutical company that commercializes VIZZ, the first and only FDA-approved aceclidine-based prescription eye drop for presbyopia in adults, sold directly in the US and through international licensing partners covering Greater China, Canada, Australia/New Zealand, the Middle East, and South Korea.
Ownership category
akta.pro rank

LENZ Therapeutics industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Presbyopia treatment
  • Ophthalmic pharmaceuticals
  • Aceclidine eye drops
  • Near vision restoration
  • Prescription eye care

Where LENZ Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LENZ Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. VIZZ Product Sales: Revenue generated from commercial sales of VIZZ (aceclidine ophthalmic solution) 1.44% in the United States through prescriptions filled at pharmacies. Early commercial traction showing 25,000 paid prescriptions in Q1 2026 with 19% sequential growth.
  2. International Licensing and Royalties: LENZ receives upfront payments, regulatory and commercial milestone payments, plus tiered royalties on net sales from international partners including Everest Medicines (up to $85M in milestones plus mid single-digit to low double-digit royalties for Greater China), Laboratoires Théa (over $70M plus tiered double-digit royalties for Canada), Arrotex (Australia/New Zealand), and Lunatus (Middle East).
  3. Private Investment (PIPE): $30 million private investment from Ridgeback Capital via a PIPE agreement to support regulatory and commercial activities.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

LENZ Therapeutics product offering

Product offering

Core offering

LENZ Therapeutics commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. The once-daily drop contracts the iris sphincter muscle to create a pinhole effect, restoring clear near vision for up to 10 hours. The company sells the product in the United States through retail pharmacies and a 117-representative sales force targeting eye care professionals, while licensing VIZZ to regional partners across Greater China, Canada, Australia/New Zealand, the Middle East, and South Korea.

Product overview

LENZ Therapeutics commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for treating presbyopia. The company developed LNZ100 and LNZ101 through Phase 3 clinical trials, with LNZ100 receiving FDA approval in July 2025 and being marketed as VIZZ. VIZZ is a once-daily prescription eye drop that improves near vision for up to 10 hours through pupil contraction creating a pinhole effect. LENZ is expanding globally through licensing partnerships while maintaining US commercialization directly.

Differentiator

Problem solved

Functional benefit

Brands

  • VIZZ: VIZZ (aceclidine ophthalmic solution) 1.44% - the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

Products and services

  • VIZZ (aceclidine ophthalmic solution) 1.44% The first and only FDA-approved aceclidine-based prescription eye drop for treating presbyopia in adults. Once-daily eye drop that improves near vision for up to 10 hours by creating a pinhole effect through pupil contraction. Validated through three Phase 3 clinical trials involving over 600 participants.

Quantifiable outcome

  • 93% of participants achieved 20/40 or better near vision within 30 minutes
  • +3 more outcomes

Companies that use LENZ Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

LENZ Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

LENZ Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and core.

  • Arrotex Pharmaceuticals Pty LtdmajorChannel Partner/ Reseller/ Distributor · 24 June 2026Exclusive licensing and commercialization agreement for VIZZ (aceclidine ophthalmic solution) in Australia and New Zealand. Arrotex receives exclusive rights to register and commercialize the presbyopia treatment while LENZ receives upfront payment plus share of gross margin from product sales. This is LENZ's fifth ex-U.S. partnership.
  • Everest MedicinesmajorChannel Partner/ Reseller/ Distributor · 7 June 2026Everest Medicines acquired rights to develop, manufacture, and commercialize VIZZ (LNZ100) for presbyopia treatment in Greater China (mainland China, Hong Kong SAR, Macao SAR, and Taiwan) through an Asset Purchase Agreement with Corxel Pharmaceuticals. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones plus tiered mid single-digit to low double-digit royalties on net sales. NDA submitted in September 2025 with approval anticipated Q1 2027.
  • Lunatus Marketing & Consulting FZCOmajorChannel Partner/ Reseller/ Distributor · 5 January 2026Exclusive distribution agreement for VIZZ (aceclidine ophthalmic solution) for treating presbyopia in the Middle East region, covering UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. LENZ receives upfront, regulatory and commercial milestone payments plus significant share of revenue. This is LENZ's fourth international commercialization partnership.
  • Lotus PharmaceuticalmajorChannel Partner/ Reseller/ Distributor · 1 December 2025Lotus Pharmaceutical submitted a New Drug Application (NDA) for VIZZ (LNZ100) in South Korea for the treatment of presbyopia following positive Phase 3 trial data. This submission marked the second regulatory step in Asia for VIZZ.
  • Laboratoires ThéamajorChannel Partner/ Reseller/ Distributor · 7 July 2025Exclusive license and commercialization agreement for LNZ100 in Canada. Théa received exclusive rights to register and commercialize the aceclidine-based eye drop candidate for treating presbyopia. LENZ eligible to receive over $70 million in upfront, regulatory, and commercial milestone payments plus tiered double-digit royalties on net sales. This was LENZ's third international commercialization agreement.
  • Graphite BiocoreStrategic or Co-development Partner · 21 March 2024LENZ Therapeutics completed a merger with Graphite Bio, with the combined company trading on NASDAQ under ticker 'LENZ' starting March 22, 2024.

Scale indicators10 records

Recent moves7 records

Expansion highlights4 records

LENZ Therapeutics competitors and assessment

Company assessment

Direct peers

  • Allergan (an AbbVie company): Allergan markets Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop and VIZZ's primary direct competitor. Same patient population (presbyopes), same delivery mechanism (topical ophthalmic drops), same prescriber base (optometrists/ophthalmologists).
  • Orasis Pharmaceuticals: Orasis is developing CSF-1 (low-dose pilocarpine) for presbyopia, positioning as another miotic-based eye drop competitor. Same therapeutic category, same target patient, same ECP channel; represents the next credible competitive threat to VIZZ's first-mover position.
  • Visus Therapeutics: Visus is developing BRIMOCHOL and other presbyopia therapeutics based on miotic mechanisms. Clinical-stage direct competitor with overlapping indication, mechanism class, and prescriber targeting.
  • Ocuphire Pharma: Ocuphire is developing ophthalmic therapeutics for presbyopia and other refractive indications, including Nyxol. Same eye-care specialty pharmaceutical model, target prescribers, and indication overlap as LENZ.

Emerging players

  • Eyenovia: Eyenovia develops ophthalmic pharmaceutical products using its Optejet dispenser platform, including presbyopia candidates (MicroLine/pilocarpine). Different delivery technology but same therapeutic indication and prescriber channel.
  • Eyedetec Medical: Eyedetec is developing pharmaceutical eye drops for presbyopia and myopia. Clinical-stage emerging competitor with same therapeutic category, though smaller and earlier-stage than LENZ.

Broad incumbents

  • Bausch + Lomb: Bausch + Lomb is a global ophthalmic company with a broad portfolio including prescription eye drops, surgical products, and consumer vision care. While not focused exclusively on presbyopia, it serves the same ECP channel and competes for eye-drop market share.
  • Alcon: Alcon is the global leader in eye care, spanning surgical, vision care, and pharmaceuticals. It is a major channel partner and a broad incumbent with overlapping ECP relationships and ophthalmic pharmaceutical capabilities.
  • Laboratoires Théa: Théa is a European ophthalmic specialty pharmaceutical company and LENZ's Canadian commercialization partner for VIZZ. Comparable specialty-ophthalmic pharma focus with similar product lines and prescriber relationships.
  • Novartis (Ophthalmology): Novartis operates a significant ophthalmology franchise (including Xiidra and Lucentis) through Sandoz and the broader pharma portfolio. Broad incumbent with overlapping eye-care prescriber relationships and ophthalmic Rx portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LENZ Therapeutics social profiles

Digital presence

LENZ Therapeutics compliance and trust

Trust signal

Compliance1 record

LENZ Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LENZ Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

LENZ Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LENZ Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LENZ Therapeutics

What does LENZ Therapeutics do?

LENZ Therapeutics commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. The once-daily drop contracts the iris sphincter muscle to create a pinhole effect, restoring clear near vision for up to 10 hours. The company sells the product in the United States through retail pharmacies and a 117-representative sales force targeting eye care professionals, while licensing VIZZ to regional partners across Greater China, Canada, Australia/New Zealand, the Middle East, and South Korea.

Is LENZ Therapeutics a public or private company?

LENZ Therapeutics is a public company. It is classified as public and is currently operating.

When was LENZ Therapeutics founded?

LENZ Therapeutics was founded in 2021. It employs 101 to 250 people.

Where is LENZ Therapeutics based?

LENZ Therapeutics is headquartered in San Diego, United States, in the North America region.

How does LENZ Therapeutics make money?

Three revenue lines are on record. VIZZ Product Sales are the primary driver. The others are international Licensing and Royalties and private Investment (PIPE).

Who are LENZ Therapeutics's main competitors?

Direct peers on record are Allergan (an AbbVie company), Orasis Pharmaceuticals, Visus Therapeutics and Ocuphire Pharma. Emerging players are Eyenovia and Eyedetec Medical. Broad incumbents are Bausch + Lomb, Alcon, Laboratoires Théa and Novartis (Ophthalmology).

Does LENZ Therapeutics have an API?

No public API is recorded for LENZ Therapeutics.

What industry is LENZ Therapeutics in?

LENZ Therapeutics's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaLENZ Therapeutics: Don't Be Tempted With This Value TrapLENZ Therapeutics remains a sell due to weak demand for its sole product VIZZ and unsustainable financials. U.S. product revenue grew only to $7.6M annually after a full year, with mounting cash burn and no R&D pipeline. The stock faces imminent dilution risk and severe operational cuts.American Banking and Market NewsLENZ Therapeutics (NASDAQ:LENZ) Stock Price Target Lowered at CitigroupCitigroup lowered its price target on LENZ Therapeutics from $10.00 to $9.00, keeping a buy rating. The company reported Q2 EPS of -$0.99, missing the -$0.89 consensus, and revenue of $3.38 million versus $4.20 million estimated. Analysts have an average rating of Hold with a consensus price target of $14.75.MarketBeatHC Wainwright Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock PriceHC Wainwright lowered its price target on LENZ Therapeutics to $16.00, keeping a buy rating. The stock opened at $3.49, and the company reported Q2 EPS of -$0.99, missing the -$0.89 consensus. Analysts have an average rating of Hold with a consensus price target of $17.50.TradingViewHC Wainwright & Co. maintains LENZ Therapeutics at Buy, lowers price target to $16 from $38HC Wainwright & Co. maintained a Buy rating on LENZ Therapeutics, cutting its price target to $16 from $38, a 57.9% reduction. The target implies a 358.5% upside from the Oct 29 close of $3.49.MarketBeatLENZ Therapeutics Q3 Earnings Call HighlightsLENZ Therapeutics reported Q3 2026 product revenue of $2.6 million, up 50% sequentially, with over 38,000 paid prescriptions for its presbyopia eye drop VIZZ. The company announced a restructuring to about 40 employees and expects operating expenses of $70-75 million in 2027. CEO Eef Schimmelpennink will step down in December 2026.FiercePharmaLenz reports 75% workforce cut, CEO shakeup alongside Q3 earnings updateLenz Therapeutics cut 75% of its workforce and is shaking up its leadership, with CEO Eef Schimmelpennink stepping down in early December. The company reported a $0.99 per share loss for Q3, exceeding estimates, and expects to finish the reorganization before the new year.TradingViewLENZ Therapeutics, Inc. Stock 12‑Month Price Target Raised to $21.43, Implies 568% UpsideAnalysts' average price target for LENZ Therapeutics rose to $21.43 from $20, implying about 568% upside from the Oct. 28 close. The consensus remains a Buy across seven analysts, with forecasts ranging from $5 to $45 per share.TradingViewLENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.17, Implies 497% UpsideAnalysts' average price target for LENZ Therapeutics fell from $20 to $19.17, implying about 497% upside from the Oct. 28 close. The consensus remains a Buy across seven analysts, with five Buys, two Holds, and no Sells.MarketBeatLENZ Therapeutics (NASDAQ:LENZ) Announces Earnings Results, Misses Expectations By $0.02 EPSLENZ Therapeutics reported Q2 EPS of -$0.99, missing the -$0.97 consensus by $0.02, and revenue of $3.38 million versus the $4.20 million estimate. The stock rose 1.9% to $3.21, while analysts hold a consensus price target of $23.00.Quiver QuantitativeLENZ Reports $3.4 Million Q3 Revenue as VIZZ Sales Rise 50% | LENZ Stock NewsLENZ Therapeutics reported Q3 2026 revenue of $3.4 million and a net loss of $31.0 million, with VIZZ product sales reaching $2.6 million, up about 50% from the prior quarter. The company announced a reorganization targeting 2027 operating expenses of $70–75 million, and CEO Eef Schimmelpennink will transition on December 1.